Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to establish whether Bimatoprost eye drops are effective in
reducing proptosis in inactive thyroid eye disease (TED) patients and improving quality of
life in patients with TED. Current standard NHS treatment/care for inactive TED is artificial
tears (used as the placebo in this study) or surgery if appropriate.
The IMP is Bimatoprost eye drops PGF2α (0.03%). This is already licensed eye drops usually
used for glaucoma. Therefore the current trial's indication is outside its licenced
indication. The Investigational Medicinal Product (IMP) will be used according to its
licenced dosage and form. This is the first time that Bimatoprost will be used in the
treatment of TED
Phase:
Phase 4
Details
Lead Sponsor:
Cardiff University
Collaborator:
National Institute for Social Care and Health Research